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PURPOSE

RESULT(S)

The main goal for this study is to develop immediate release Fused Deposition Modeling (FDM)
3D printed loratadine tablets using hot-melt extruded filaments..

All formulations were successfully extruded in a four conveying zones
and three mixing zones. The filaments were white to off-white in color.
The torque and die pressure were within an acceptance range with 50
rpm screw speed. Based on the filament’s mechanical properties, six
filaments (F3, F5, F6, F7, F9, F10) out of ten were printable (Table 2).
Greater breaking stress is a sign of harder filament texture. While a
longer breaking distance implies a softer filament. Higher breaking
stresses or breaking distances indicate increased brittleness. When
the filament has a higher stiffness value (k), printability will be
improved, as the resistance of filament to deformation increases. The
loratadine DSC thermograms showed an endothermic melting peak at
134.5 °C. On the other hand, this endothermic peak disappeared in the
extruded filament as well as the 3D-printed tablets indicating complete
solubilization of loratadine in the polymeric carrier for all 6 formulations
(Figure 1). Loratadine has characteristic absorption bands at 1699
cm−1 (C=O stretching), 1433 cm−1 (-C-O stretching ), 1219 cm−1
(Aryl -C-N stretching ), and 996 cm−1 (Aryl C-Cl stretching). In Figure
2 when comparing pure loratadine with the extrudate, (C=O) peak
shifted to a higher wavelength, (-C-O) band broadened and shifted to a
higher wavelength indicating that loratadine interacted and solubilized
within the polymer. The tablets were printed in a grid pattern and with
40% to 60% infill to accelerate the drug release (Figure 3). The target
weight was 100 mg and most of the tablets had a weight between 95
and110 mg. Loratadine content of 3D printed tablets were 87.24%113.90%. All 3D printed tablets disintegrated within 15 minutes. The
drug release from the printed tablets “F3(40%infill), F5(40%infill),
F9(40%infill), F10(40%infill)” showed 89.2%, 86.1%, 85.8%, and
96.8% respectively in 30 minutes (Figure 4). .

OBJECTIVE(S)
• Optimize the formulation composition and HME processing parameter to extrude filaments that
can be fed into an FDM-3D printer and perform as an immediate release.
• Designing the 3D printed tablet and optimize the 3D printing sittings.
• Evaluate the 3D printed tablets.

METHOD(S)
Formulation optimization and HME: Loratadine was used as a model drug with 10% (w/w) drug
loading. Crospovidone (Polyplasdone XL) and croscarmellose sodium were used as superdisintegrants, to facilitate tablets` disintegration, dissolution, and the release of loratadine from the
formulations. Mannitol was used as a pore-forming agent to enhance the dissolution. Polyethylene
Glycol 1500 (PEG-1500) was used as a plasticizer. Polyethylene oxide N80 (PEO N80) and
hydroxypropyl cellulose EF (HPC-EF) were used as polymeric carriers. The physical mixtures of
the selected formulations (Table1) were then extruded using an 11 mm twin-screw co-rotating
extruder (Process 11 twin-screw extruder Thermo Fisher Scientific, Waltham, MA, USA).
Three-point bend test: Performed using a texture analyzer (TA-XT2i Texture Analyzer by Stable
Micro Systems, UK), to evaluate the printability of the extruded filaments. The filament placed on a
sample holder with a 25 mm gap, the blade speed was set at 10 mm/s for pre-test speed, test
speed, and post-test speed, the distance at 10 mm, and the trigger force at 5 g.
FDM-3D printing: The printable filaments were printed using an FDM-3D printer (Prusa i3 3D
desktop printer, Prusa Research, Prague, Czech Republic) with 40% to 60% infill, and Grid pattern
Weight variation: Ten tablets of each formulation were weighed using an analytical balance.
Drug assay: To evaluate drug content and uniformity of physical mixtures, filaments, and tablets.
Disintegration test: The disintegration time was evaluated using a disintegration apparatus
(Dr.Schleuniger® Pharmatron DT2-IS Disintegration Tester, Uttigenstrasse 28, 3600 Thun,
Switzerland). 1 L of 0.1 N HCl (pH 1.2) medium was used and maintained at 37 °C for 15 minutes.
In-vitro drug release study: The release profile of printed tablets was evaluated using a United
States Pharmacopeia (USP) dissolution apparatus II (Hanson Research Virtual Instruments SR8
Plus, Los Angeles, CA). The dissolution medium was 900 mL 0.1 N HCl (pH 1.2), maintained at
37°C and 50 rpm. A sample of 2 mL was withdrawn at time points 3, 6, 10, 15, 11, 30, 45, and 60
minutes, centrifuged for 10 minutes at 25°C at 13,000 rpm, and then analyzed using HPLC.
HPLC analysis: Performed to evaluate drug assay and In-vitro drug release, using Waters HPLCUV system (Waters Corporation, Milford, MA, USA). Phenomenex C8 column (5 microns, 150 *
4.6 mm) was used and the test conditions were set up as follows: column temperature 30°C, flow
rate 1mL/minute, injection volume 10µL, loratadine detection wavelength at 247 nm. The mobile
phase consisted of phosphate buffer pH 6 methanol (20:80).
Differential scanning calorimetry (DSC): The physical mixtures, filaments, and 3D-printed
tablets were analyzed using a (TA DSC 25) with a heating rate of 10 °C/min from 25 to 250 °C, to
determine the physical state of loratadine.
Fourier transform infrared spectroscopy (FTIR): Performed to investigate the interactions
between loratadine and the polymeric carriers using an Agilent Cary 660 (Agilent Technologies,
Santa Clara,CA, USA).

Figure2. FTIR spectra for F3, over a 600–4000 cm−𝟏 range

Table 2. 3-point bend test.

Figure 3. 3D-printed tablets, grid pattern with different %infill.

Table 1. Loratadine formulations` compositions.

CONCLUSION(S)
Formulation development of loratadine immediaterelease tablets using hot-melt extrusion coupled
with FDM 3D-printing technology was studied and
presented. The HME process was shown to have
a great potential to develop filaments which were
suitable for FDM-3D printing of immediate release
loratadine tablets. The percent infill, printing
pattern, and the formulation compositions are
critical variables in the development of an
immediate-release for loratadine 3D printed
tablets. An accurate tablet weight can be achieved
using FDM-3D printing technology.
Extruded filaments from formulation numbers F3,
F5, F6, F7, F9, and F10 were printable, and the
printed tablets except for F7 (no superdisintegrant) met the dissolution criteria of 80%
released within 30 minutes. F3 and F10 containing
polyplasdone XL alone in F3 and a combination of
polyplasdone XL and croscarmellose sodium as a
super-disintegrants in F10, and PEO N80 as a
polymeric carrier showed the fastest loratadine
disintegration and dissolution profile. When
comparing all formulations, F10 had faster
dissolution profile, in this formulation the superdisintegrant used was a combination of
polyplasdone XL (5% w/w) and croscarmellose
sodium (5% w/w). The disintegration times for the
printed tablets ranged from 8 to 12 minutes for the
immediate-release printed tablets. Loratadine
content was within the acceptance range in both
the extruded filaments and the 3D printed tablets.
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